Stockreport

bluebird bio to Present New Data from Early- and Late-Stage Pipeline of Investigational Gene and Cell Therapies at the American Society of Hematology Annual Meeting

bluebird bio, Inc.  (BLUE) 
Last bluebird bio, inc. earnings: 2/18 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.bluebirdbio.com/investor-overview
PDF – Initial data from Phase 3 studies of LentiGlobin™ gene therapy in transfusion-dependent ß-thalassemia for ß0/ß0 genotype and updated data in non-ß0/ß0 [Read more]